decrease in OME's prescribed with increasing age by decade was only seen in the opioid naïve group. Pain scores were directly correlated to the amount of opioid prescribed in both groups (p>0.01); the absence of a statistically significant age-related trend in OME's prescribed for pre-operative opioid users (541 to 226 from youngest to oldest, p¼0.056) is likely due to a lack of power in this smaller group. CONCLUSION: Among patients undergoing POP surgery, preoperative opioid users had higher mean pain scores, were prescribed more OME's and had higher opioid refill rates. They were also, younger, of higher BMI and less likely to be white. In both preoperative opioid using and opioid naïve groups, younger patients had higher pain scores and opioid refill rates.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD OBJECTIVES: Women with refractory urgency urinary incontinence (UUI) can be treated with onabotulinumtoxinA (BTX) or sacral neuromodulation (SNM). The goal of this study was to compare the impact of these treatments on bowel and sexual function. MATERIALS AND METHODS: This was a planned supplemental analysis of a randomized trial in women with refractory UUI treated with BTX (n¼190) or SNM (n¼174). Bowel and sexual symptoms were measured at baseline, 6, 12, and 24 months. Bowel symptoms were measured using the St Mark's (Vaizey) Fecal Incontinence severity scale. Sexual symptoms were measured using the Pelvic Organ Prolapse/Urinary Incontinence Sexual and the Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR). The PISQ-IR allows calculation of 6 subscores for sexually active women (SA-AO: Arousal, Orgasm; SA-PR: Partner Related; SA-CS: Condition Specific; SA-GQR: Global Quality Rating; SA-CI: Condition Impact; SA-D: Desire) and 4 subscores for those not sexually active (NSA-PR; NSA-CS; NSA-GQR; and NSA-CI). Primary outcome was change in Vaizey and PISQ-12 scores between baseline and 6 months. Secondary outcomes were change in PISQ-IR scores between baseline and 6 months and change in Vaizey, PISQ-12 and PISQ-IR scores between baseline and 12 and 24 months. Intent to treat analysis was performed using repeated measures mixed model to estimate change in all parameters from baseline while adjusting for the baseline score. A subgroup analysis of women with clinically significant bowel symptoms was conducted based on baseline Vaizey score of 12.
RESULTS: There were no differences between BTX and SNM groups in baseline Vaizey (7.6+5.3 v 6.6+4.9, p¼0.07), p¼0.55) , or PISQ-IR subscores. 39% in BTX and 45% in SNM group were sexually active at baseline (p¼0.25). There was no difference between women treated with BTX and SNM at 6 months in improvement in Vaizey score (-1.9, 95% CI -2.6 to -1.2 v -0.9, 95% CI -1.7 to -0.2, p¼0.07) or PISQ-12 score (2.2, 95% CI 0.7 to 3.7 v 2.2, 95% CI 0.7 to 3.7, p¼0.99). There was no difference in improvement between groups in the PISQ-IR subscores at 6 months, or the Vaizey, PISQ-12, and PISQ-IR subscores at 12 and 24 months. In a subgroup (BTX¼33 and SNM¼22) with baseline Vaizey score 12, there was a clinically important improvement in bowel symptoms in both groups from baseline to 6 months with no difference in improvement between the BTX and SNM groups (-5.1, 95% CI -7.3 to -2.8 v -5.6, 95% CI -8.5 to -2.6, p¼0.8). CONCLUSION: There were no differences in improvement of bowel and sexual symptoms in women with UUI treated with BTX or SNM. Women with clinically significant bowel symptoms at baseline had improvement in symptoms although there was no difference between the treatments. Our findings may not pertain to a fecal incontinence or sexual dysfunction treatment-seeking group. OBJECTIVES: For some patients with both rectal and vaginal prolapse, a perineal approach to combined prolapse repair with rectal fixation would improve prolapse outcomes and be less morbid than an abdominal approach. Utilization of the sacrospinous ligaments and uterosacral ligaments for vaginal apical suspension has been well described with good surgical outcomes and improvement in vaginal prolapse symptoms. Here, we describe using the sacrospinous ligament and uterosacral ligament as a point of fixation for rectal prolapse and vaginal prolapse via a transvaginal approach. MATERIALS AND METHODS: Patients with full thickness rectal prolapse and symptomatic pelvic organ prolapse underwent concurrent rectopexy and vaginal vault suspension with the following steps: 1. Exposure of the sacrospinous ligaments through an extra-peritoneal approach or exposure of the uterosacral ligaments through an intraperitoneal approach. 2. Placement of two or three absorbable sutures through the bilateral ligaments. 3. Placement of an EEA sizer in the rectum and fixation of the sutures through the proximal and distal anterior rectal wall. 4. Suspension of the vagina and rectum by bringing the sutures through the vaginal cuff. 5. Performance of a rectal exam to ensure minimal tension on the rectum.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS:

RESULTS:
Sacrospinous rectopexy and uterosacral rectopexy were performed in two patients. Both patients had full thickness rectal prolapse and Stage 3 pelvic organ prolapse with surgical history significant for multiple abdominal surgeries. The first patient underwent a Delorme mucosal resection, sacrospinous rectopexy and sacrospinous vaginal vault suspension. Total surgical time was 146 minutes and time to perform the sacrospinous rectopexy/vaginal vault suspension was 93 minutes. The second patient underwent a Delorme mucosal resection, hysterectomy, uterosacral rectopexy and uterosacral vaginal vault suspension. Total surgical time was 229 minutes and time to perform the uterosacral rectopexy/vaginal vault suspension was 100 minutes. No recurrence of vaginal or rectal prolapse was noted 30 days after surgery. CONCLUSION: We describe two novel techniques of rectal and vaginal apical fixation using the perineal approach for combined rectal and pelvic organ prolapse. This multidisciplinary approach has the opportunity to provide excellent suspension with good long-term durability and low perioperative morbidity for elderly women with combined urogenital and rectal prolapse. We are conducting an IRBapproved review of the long-term follow-up of these patients to establish outcomes, recurrence rates, and comparison to other available procedures. Transvaginal sacrospinous rectopexy and colpopexy and transvaginal uterosacral ligament rectopexy and colpopexy are both minimally invasive and technically feasible techniques for the treatment concomitant rectal prolapse and vaginal prolapse.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS:
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75 Effectiveness of botulinum toxin injection to the pelvic floor for treatment of pelvic floor myofascial pain in women: a systematic review and meta-analysis OBJECTIVES: Botulinum toxin has been successfully used for treatment of myofascial pain disorders throughout the body, and emerging evidence supports a role for this agent in treatment of pelvic floor myofascial pain as well. The objective of this study was to systematically review the literature and synthesize the evidence for the effectiveness of botulinum toxin injection to the pelvic floor muscles for pelvic floor myofascial pain in women. MATERIALS AND METHODS: This systematic literature search was performed using strategies for the concepts of Botulinum Toxin Type A, BotoxÒ, pelvic floor, pelvic pain and myofascial pain syndromes in PubMed/Medline 1946-, EMBASE 1947-, Scopus 1823-, Cumulative Index of Nursing and Allied Health Literature (CINAHL) 1937-, Web of Science 1900-, PEDro 1929-Cochrane Library and Clinicaltrials.gov. The primary outcome of interest was change in pain score after botulinum toxin injection. Secondary outcomes including dysmenorrhea, dyspareunia, dyschezia, quality of life, and manometry pressures were also analyzed. RESULTS: The initial search identified 4448 publications, of which 2016 were duplicates and were removed. We screened the resulting 2432 abstracts and excluded 2313 based on predefined inclusion and exclusion criteria. During screening, an additional 2 relevant articles were identified through reference search, resulting in 121 full text articles reviewed. After completion of full text review, 9 studies met criteria for inclusion. During data analysis, 2 studies were excluded due to inability to extract data since pre-and post-treatment quantitative pain scores were not reported. In total, 7 studies were included with 214 patients.
Pelvic floor botulinum toxin injection was associated with a 28.8 point reduction in pain scores (95% CI, 14.8-42.8). Improvement was also noted in secondary outcomes including dysmenorrhea, dyspareunia, dyschezia, and quality of life. CONCLUSION: This systematic review and meta-analysis supports the use of transvaginal botulinum toxin injection to the pelvic floor for treatment of pelvic floor myofascial pain and associated pelvic floor symptoms.
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OBJECTIVES:
The most common occult malignancy in gynecologic surgery is uterine cancer. Unintentional spillage of cells can occur during morcellation and subtotal hysterectomy performed with supportive repair. While available screening for endometrial cancer may reduce the risk of occult malignancy, it is not cost effective in the asymptomatic patient. One diagnostic method that has not been explored for the uterine body, but has shown promise in cervical, breast, prostate, and skin cancer is bioimpedance analysis. Bioimpedance is a non-invasive technique that measures the pattern of current flow through biological tissue, which is determined by the architecture of its cells. An organ that harbors a malignancy will have cellular changes throughout to support the invasive tumor. We hypothesize that benign and tumor-bearing uterine tissue can be differentiated by its electrical characteristics. MATERIALS AND METHODS: We collected 8 whole ex-vivo uterine specimens at the time of hysterectomy. A two-armed probe with electrodes at the end of each arm was designed for this study. The probe measures impedance spectra over the range of 10 kHz to 1 MHz. Immediately following removal from the body, the cervix was serially dilated to allow for passage of the probe's lower arm into the endometrial cavity. Representative sites over the uterine specimen were sampled. Pathology confirmed 4 benign (non-tumor-bearing) and 4 malignant (tumor-bearing) uterine samples. The impedance data was then studied with multiple instance learning and principal component analysis (PCA). RESULTS: Impedance data plotted using PCA appears to visually separate between each diagnoses. A decision boundary value of -0.3 distinguishes benign from malignant runs. The confusion matrix indicates an error rate of 20.55% in reliably predicting benign specimens, and an error rate of 12.75% in reliably predicting malignant specimens as confirmed by pathologic evaluation. CONCLUSION: Our results show distinction between electrical impedance of tumor-bearing and non-tumor-bearing uterine specimens. Analysis was performed with multiple instance learning, an artificial intelligence technique. These results are encouraging since the data indicates that the presence of tumor within any
